



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

17 January 2025
EMA/CVMP/592483/2024
Committee for Veterinary Medicinal Products

Summary of opinion (initial authorisation)

Nobilis Multiriva REOm

Common name: Avian reovirus, strain ARV-1, Inactivated, Avian reovirus, strain ARV-4, Inactivated

On 15 January 2025, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the veterinary medicinal product Nobilis Multiriva REOm, emulsion for injection, intended for chicken. The applicant for this veterinary medicinal product is Intervet International B.V.

Nobilis Multiriva REOm is an immunological veterinary medicinal product containing inactivated avian reovirus strain ARV-1 and inactivated avian reovirus strain ARV-4 as active substances (ATCvet code QI01AA04).

The benefit of Nobilis Multiriva REOm is the active immunisation of chickens for passive immunisation of the progeny of the vaccinated chickens to reduce viraemia and clinical signs of disease caused by avian reovirus (ARV) genotypes 1 and 4.

The onset of immunity is 4 weeks post-vaccination after booster vaccination and 1 day of age in the progeny. The duration of immunity is 80 weeks post-vaccination after booster vaccination and 3 weeks of age in the progeny.

Cross-protection has been established for ARV genotypes 2, 3 and 5.

Nobilis Multiriva REOm is generally well tolerated at the recommended dose. The most common side effects are injection site lumps after vaccination which generally disappear within 3 weeks.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Nobilis Multiriva REOm and therefore recommends the granting of the marketing authorisation.

